menu
    • menu
    [{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"EPI Health","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Luliconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Cream","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Sato Yakuhin Kogyo Co., Ltd

    Menu

    Sato Yakuhin Kogyo Co., Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : Arcutis Biotherapeutics

                            Deal Size : $40.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arcutis and Sato Announce Strategic Collaboration for Topical Roflumilast in Japan

                            Details : The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.

                            Product Name : Zoryve

                            Product Type : Miscellaneous

                            Upfront Cash : $25.0 million

                            February 28, 2024

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : Arcutis Biotherapeutics

                            Deal Size : $40.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : EPI Health

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RH...

                            Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...

                            Product Name : Rhofade

                            Product Type : Miscellaneous

                            Upfront Cash : $5.0 million

                            December 21, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : EPI Health

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luliconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis

                            Details : Luliconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Onychomycosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 08, 2021

                            Lead Product(s) : Luliconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth